Overview: Haptoglobin Genotyping TestIntroduction: The Haptoglobin Genotyping Test detects haptoglobin gene variants to assess hemolytic anemia or cardiovascular risk, causing fatigue or chest pain. Following 2023 ASH guidelines, it uses an immunoassay for high specificity, aiding in genetic screening. This test is critical for guiding risk assessment, treatment, and improving outcomes in molecular pathology for patients with suspected hemolytic or cardiovascular conditions.
Other Names: Haptoglobin Geno Assay, Haptoglobin Genetic Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Haptoglobin genotyping began in the 2000s with genetic research on hemolysis and cardiovascular risk. Immunoassays improved in the 2010s, enhancing specificity.
Purpose: Assesses hemolytic anemia or cardiovascular risk, guides treatment, and monitors haptoglobin gene variants in patients with fatigue or chest pain.
Test Parameters: 1. Haptoglobin Genotype
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva at any time. Report symptoms like fatigue or chest pain, and list medications.
Specimen: 2-5 mL whole blood (EDTA), 1-2 buccal swabs (sterile swab), or 1-2 mL saliva (sterile container). Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document fatigue, chest pain, or history of hemolytic anemia or cardiovascular disease. Include current medications and family history.
Consent: Written consent required, detailing the tests purpose, genetic implications, and potential need for targeted therapy.
Procedural Considerations: Uses an immunoassay to detect haptoglobin gene variants (e.g., Hp1, Hp2). Results are available in 3-5 days, supporting clinical decisions.
Factors Affecting Result Accuracy: Poor DNA quality, contamination, or improper storage can affect results. Rare variants may require additional testing.
Clinical Significance: Specific haptoglobin genotypes (e.g., Hp2-2) indicate higher cardiovascular risk or hemolytic propensity, guiding management. Normal genotypes may require further evaluation.
Specialist Consultation: Consult a hematologist or cardiologist for result interpretation and risk management.
Additional Supporting Tests: Haptoglobin level, lipid profile, or cardiac imaging to assess cardiovascular or hemolytic risk.
Test Limitations: Rare variants may not be detected. Results require clinical correlation and additional testing.
References: ASH Genetic Screening Guidelines, 2023; Blood, Schrier SL, 2022.
